NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Surgery Partners Stock Plunges 25% on Lowered Revenue Outlook

Surgery Partners shares hit five-year low after cutting full-year guidance due to weaker patient volumes and insurance payment trends in Q3 2025.

Surgery Partners Stock Plunges 25% on Lowered Revenue Outlook
Photo by Piron Guillaume on Unsplash
Already have an account? Sign in.
11/10/2025 · 2:40 PM
SGRY
/ Read more

Feed↓

Prelude Shares Jump as Incyte Drops Rival JAK2 Drug
Featured/ 07/28/2026 · 1:04 PM

Prelude Shares Jump as Incyte Drops Rival JAK2 Drug

Prelude Therapeutics stock rises after Incyte discontinues INCB160058 to focus on next-gen JAK2V617F therapies, boosting its exclusive option deal.

/ Subscriber only
FDA Raises Serious Doubts Over Replimune’s RP1 Melanoma Therapy Ahead of Key Panel
Featured/ 07/28/2026 · 12:39 PM

FDA Raises Serious Doubts Over Replimune’s RP1 Melanoma Therapy Ahead of Key Panel

FDA briefing docs criticize Replimune’s RP1 trial data, raising doubts over effectiveness and sending shares down ahead of Thursday’s panel.

/ Subscriber only
Repligen Beats Q2 Estimates, Raises 2026 Guidance on Strong Bioprocessing Demand
07/28/2026 · 12:14 PM

Repligen Beats Q2 Estimates, Raises 2026 Guidance on Strong Bioprocessing Demand

Repligen posts $204M Q2 revenue (+12%), adjusted EPS of $0.54 beating estimates. Raises FY26 organic growth to 10.5%-13.5% and EPS to $2.03-$2.09.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe